Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 92

Sort by

Sort Order Select

Journal Articles

Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies

Angelo Belotti, Paola Maestri, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Samantha Ferrari, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Marco Chiarini, Viviana Giustini, Michele Malagola, Aldo Roccaro, Alessandra Tucci

Blood (2025) 146 (Supplement 1): 4040.

https://doi.org/10.1182/blood-2025-4040

Published: 2025

Journal Articles

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Blood (2025) 146 (Supplement 1): 3438.

https://doi.org/10.1182/blood-2025-3438

Published: 2025

Journal Articles

Impact of MYC alterations in de novo large B-cell lymphoma: An italian single center experience

Chiara Pagani, Alessandro Re, Angela Passi, Rosa Daffini, Francesca Schieppati, Antonella Anastasia, Marina Motta, Ester Lovato, Chiara Cattaneo, Simone Maifredi, Alessia Pantaleo, Luisa Lorenzi, Piera Balzarini, Alessandra Tucci

Blood (2025) 146 (Supplement 1): 5443.

https://doi.org/10.1182/blood-2025-5443

Published: 2025

Journal Articles

First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Blood (2025) 146 (Supplement 1): 5102.

https://doi.org/10.1182/blood-2025-5102

Published: 2025

Journal Articles

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Thomas Cluzeau, Pierre Yves Dumas, Pau Montesinos, Gaia Ciolli, Céline Berthon, Felicetto Ferrara, Adriano Venditti, José Antonio Pérez-Simón, Maria Calbacho, Richard Noppeney, Monia Lunghi, Chiara Cattaneo, Fabrizio Pane, Francesco Lanza, Juan Miguel Bergua Burgues, Alessandro Isidori, Yngvar Floisand, Vinay Jain, Eunice Wang

Blood (2025) 146 (Supplement 1): 767.

https://doi.org/10.1182/blood-2025-767

Published: 2025

Journal Articles

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Blood (2025) 146 (Supplement 1): 5243.

https://doi.org/10.1182/blood-2025-5243

Published: 2025

Journal Articles

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Blood (2025) 146 (Supplement 1): 2685.

https://doi.org/10.1182/blood-2025-2685

Published: 2025

Journal Articles

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Blood (2025) 146 (Supplement 1): 5678.

https://doi.org/10.1182/blood-2025-5678

Published: 2025

Journal Articles

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Blood (2025) 146 (Supplement 1): 1890.

https://doi.org/10.1182/blood-2025-1890

Published: 2025

Journal Articles

Infectious complications in elderly newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: Comparison with a historical control group treated with intensive chemotherapy

Chiara Cattaneo, Lisa Colleoni, Mirko Farina, Laura Donatoni, Lorenzo Masina, Simone Maifredi, Erika Borlenghi, Francesca Federico, Alessandra Tucci, Michele Malagola

Blood (2025) 146 (Supplement 1): 6895.

https://doi.org/10.1182/blood-2025-6895

Published: 2025

Journal Articles

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2891.

https://doi.org/10.1182/blood-2024-207842

Published: 2024

Journal Articles

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

Angelo Belotti, Barbara Frittoli, Sofia Terlizzi, Rossella Ribolla, Claudia Crippa, Chiara Saeli, Samantha Ferrari, Annalisa Peli, Nicola Bianchetti, Chiara Bottelli, Chiara Cattaneo, Carmela Carbone, Alessandro Gullino, Marco Chiarini, Viviana Giustini, Aldo Roccaro, Luigi Grazioli, Alessandra Tucci

Blood (2024) 144 (Supplement 1): 82.

https://doi.org/10.1182/blood-2024-198779

Published: 2024

Journal Articles

Venetoclax and Hypomethylating Agents Confirmed to be Standard Therapy in De Novo and ELN17 Not Adverse Acute Myeloid Leukemia Patients, Unfit for Chemotherapy According to SIE/Sies/GITMO Criteria. a Multicentric Real-Life Study on 379 Patients, By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2024) 144 (Supplement 1): 2863.

https://doi.org/10.1182/blood-2024-202530

Published: 2024

Journal Articles

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Blood (2023) 142 (Supplement 1): 956.

https://doi.org/10.1182/blood-2023-180568

Published: 2023

Journal Articles

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 1536.

https://doi.org/10.1182/blood-2023-184678

Published: 2023

Journal Articles

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Chiara Cattaneo, Massimo Bernardi, Nicola Fracchiolla, Federica Gigli, Claudia Basilico, Lorenzo Masina, Erika Borlenghi, Alessandro Bruno, Giselda Gela, Diego Bertoli, Giuseppe Rossi, Alessandra Tucci, Federico Lussana, Elisabetta Todisco

Blood (2023) 142 (Supplement 1): 5827.

https://doi.org/10.1182/blood-2023-181212

Published: 2023

Journal Articles

Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients

Blood (2023) 142 (Supplement 1): 2070.

https://doi.org/10.1182/blood-2023-184455

Published: 2023

Journal Articles

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Blood (2023) 142 (Supplement 1): 2918.

https://doi.org/10.1182/blood-2023-189417

Published: 2023

Journal Articles

Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes

Blood (2023) 142 (Supplement 1): 5845.

https://doi.org/10.1182/blood-2023-189358

Published: 2023

Journal Articles

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Livio Pagano, Jon Salmanton-García, Francesco Marchesi, Ola Blennow, Maria Gomes da Silva, Andreas Glenthøj, Jaap van Doesum, Yavuz M. Bilgin, Alberto López-García, Federico Itri, Raquel Nunes Rodrigues, Barbora Weinbergerová, Francesca Farina, Giulia Dragonetti, Caroline Berg Venemyr, Jens van Praet, Ozren Jaksic, Toni Valković, Iker Falces-Romero, Sonia Martín-Pérez, Moraima Jiménez, Julio Dávila-Valls, Martin Schönlein, Emanuele Ammatuna, Stef Meers, Mario Delia, Zlate Stojanoski, Anna Nordlander, Tobias Lahmer, László Imre Pinczés, Caterina Buquicchio, Klára Piukovics, Irati Ormazabal-Vélez, Nicola Fracchiolla, Michail Samarkos, Gustavo-Adolfo Méndez, José-Ángel Hernández-Rivas, Ildefonso Espigado, Martin Cernan, Verena Petzer, Sylvain Lamure, Roberta di Blasi, Joyce Marques de Almedia, Michelina Dargenio, Monika M. Biernat, Mariarita Sciumè, Cristina de Ramón, Nick de Jonge, Josip Batinić, Avinash Aujayeb, Monia Marchetti, Guillemette Fouquet, Noemí Fernández, Giovanni Zambrotta, Maria Vittoria Sacchi, Anna Guidetti, Fatih Demirkan, Lucia Prezioso, Zdeněk Ráčil, Marcio Nucci, Miloš Mladenović, Raphaël Liévin, Michaela Hanáková, Stefanie Gräfe, Uluhan Sili, Marina Machado, Chiara Cattaneo, Tatjana Adžić-Vukičević, Luisa Verga, Jorge Labrador, Laman Rahimli, Matteo Bonanni, Francesco Passamonti, Antonio Pagliuca, Paolo Corradini, Martin Hoenigl, Philipp Koehler, Alessandro Busca, Oliver A. Cornely

Blood (2022) 140 (26): 2773–2787.

https://doi.org/10.1182/blood.2022017257

Published: 2022

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Reassessing ASCT in patients aged 65–75 with multiple myeloma in the era of anti-CD38 therapies

Elderly Acute Myeloid Leukemia (AML) with NPM1 or FLT3-ITD mutated: Is venetoclax the game changer also in fit patients? a real-life retrospective analysis by the rete ematologica lombarda

Impact of MYC alterations in de novo large B-cell lymphoma: An italian single center experience

First report of the GIMEMA INO-first multicenter observational study analyzing infective and non-infective complications in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin.

Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial

Mynerva-gimema AML1919 ameliorate Trial: EARLY intensification in FLT3-mutated ACUTE myeloid leukemia based on peripheral blast clearance

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Chronic obstructive pulmonary disease and prior pneumonia as predictors of infectious risk in chronic lymphocytic leukemia patients receiving acalabrutinib or zanubrutinib: A seifem multicentre Study.

Post-transplant lymphoproliferative disorders in adult transplant recipients: Preliminary results of the multicenter italian FIL_PTLD study

Infectious complications in elderly newly diagnosed acute myeloid leukemia patients treated with hypomethylating agents with or without venetoclax: Comparison with a historical control group treated with intensive chemotherapy

Survival Analysis of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Early Identification of Functional High Risk Multiple Myeloma Patients after Transplant with Diffusion-Weighted Whole-Body MRI: Predictive Role of Fat Fraction in Addition to RAC Score

SIE/Sies/GITMO Criteria in Elderly Patients with Acute Myeloid Leukemia (AML): Useful Also in the New Drug Era? a Multicentric Real-Life Study By the Hematological Network Rete Ematologica Lombarda (REL)

Final Analysis for the Primary End-Point of Gimema AML1718, a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Different Epidemiology and Characteristics of Invasive Pulmonary Aspergillosis in Acute Lymphoid Leukemia in Comparison with AML: Results of a Prospective Multicentric Observational Study of the Rete Ematologica Lombarda (REL)

Autologous Stem Cell Transplantation before Lymphocyte Apheresis for CAR-T Cells Therapy Negatively Impacts on T-Cells Fitness and NK Cell Levels in DLBCL Patients

Single Agent Tagraxofusp in Relapsed/Refractory CD123-Positive Acute Myeloid Leukemia: A Preliminary Analysis of Italian Gimema AML2020 Trial

Gimema Seifem Real-Life Study VS Randomized CPX-351 Registrative Trial for Older Patients with Secondary ACUTE Myeloid Leukemia: An Unanchored Matching-Adjusted Indirect Comparison of Infection Rates and Survival Outcomes

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only